Appoints Dr. Shane Morris CPO and André Jérôme
CIO
TSX | NYSE: ACB
EDMONTON, Nov. 20, 2019 /CNW/ - Aurora Cannabis Inc.
(the "Company" or "Aurora") (NYSE │ TSX: ACB), the Canadian
company defining the future of cannabis worldwide, is pleased
to announce that effective immediately, Dr. Shane Morris, formerly Senior Vice President of
Product Development and Regulatory Affairs, has been promoted to
Chief Product Officer, and André Jérôme, formerly Senior Vice
President of Business Integrations, has been promoted to Chief
Integration Officer.
"Aurora is committed to maintaining its global leadership
position in the cannabis industry and we have built a strong team
that will drive the future growth and strategic development of the
business," said Terry Booth, CEO.
"Shane has played a critical role in overseeing Aurora's product
development and regulatory initiatives which have resulted in the
successful launch of many novel product forms and the successful
management of our many site licences. As we enter the next phase of
consumer legalization in Canada
and global expansion, Shane will play a critical role in ensuring
we continue to have the right mix of products in all markets that
will resonate with both our patients and consumers."
Mr. Booth added, "With diverse business integration experience,
André has played a critical role in the successful integration of
our global assets and subsequently ensuring we continue to drive
strong value from these transactions for our investors. André's
contributions have allowed us to strategically assemble a portfolio
of high-quality assets that together are uniquely positioned to
continue to lead the global cannabis industry."
Chief Product Officer
Dr. Morris joined Aurora in January
2018 to lead the Company's product development and
regulatory affairs initiatives. Committed to science-based,
consumer-focused innovation, Dr. Morris has led the development,
regulatory oversight and market introduction for several of the
Company's innovative cannabis products, including Aurora's Oral
Mist, Oral Dissolve Strips, and Aurora
Cloud, the first-ever vape-ready oil cartridge to be
introduced under Health Canada regulations. In his new role, Dr.
Morris will be responsible for the Company's product development
for the Canadian and international markets. Dr. Morris holds a
Ph.D. in plant science and policy from the National University of Ireland (NUI), Galway and a
B.Sc. in biology and mathematics from NUI, Maynooth.
Chief Integration Officer
Mr. Jérôme joined Aurora in February
2018 through the acquisition of H2 Biopharma which now
operates as the Company's Aurora Eau facility in Lachute, Quebec. Initially responsible for the
integration of Aurora's acquisitions as well as the identification
of synergies across existing subsidiaries and joint venture
partners, Mr. Jérôme's role has expanded over the last 18 months to
include Global Security, Health, Safety & Environment, and
oversight for a number of subsidiaries. As Chief Integration
Officer, André will oversee all current and future integrations
with a focus on value generation to support the Company's expansion
strategy. Mr. Jérôme has led the successful integration of many of
Aurora's largest business assets including CanniMed Therapeutics,
MedReleaf, Whistler Cannabis and Anandia Laboratories.
About Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 625,000 kg per
annum and sales and operations in 25 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high-quality consistent product. Designed to be replicable and
scalable globally, our production facilities are designed to
produce cannabis at significant scale, with high quality,
industry-leading yields, and low-per gram production costs. Each of
Aurora's facilities is built to meet European Union Good
Manufacturing Practices ("EU GMP") standards. Certification has
been granted to Aurora's first production facility in Mountain View
County, the MedReleaf Markham facility, and its wholly owned
European medical cannabis distributor Aurora Deutschland. All
Aurora facilities are designed and built to the EU GMP
standard.
In addition to the Company's rapid organic growth and strong
execution on strategic M&A, which to date includes 17 wholly
owned subsidiary companies – MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland, H2 Biopharma, BC Northern
Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia,
HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs,
Whistler, Chemi Pharmaceutical, and Hempco – Aurora is
distinguished by its reputation as a partner and employer of choice
in the global cannabis sector, having invested in and established
strategic partnerships with a range of leading innovators,
including: Radient Technologies Inc. (TSXV: RTI), Cann Group Ltd.
(ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom
Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH),
Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI), EnWave
Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group
(private), and Wagner Dimas (private).
Aurora's Common Shares trade on the TSX and NYSE under the
symbol "ACB", and is a constituent of the S&P/TSX Composite
Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com
Terry Booth, CEO
Aurora Cannabis Inc.
Forward looking statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. These statements are only predictions.
Various assumptions were used in drawing the conclusions or making
the projections contained in the forward-looking statements
throughout this news release. Forward-looking statements are based
on the opinions and estimates of management at the date the
statements are made, and are subject to a variety of risks and
uncertainties and other factors that could cause actual events or
results to differ materially from those projected in the
forward-looking statements. The Company is under no obligation, and
expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable law.
Neither TSX, NYSE nor their applicable Regulation Services
Providers (as that term is defined in the policies of the Toronto
Stock Exchange and New York Stock Exchange) accept responsibility
for the adequacy or accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-strengthens-leadership-team-adding-chief-product-officer-and-chief-integration-officer-300961565.html
SOURCE Aurora Cannabis Inc.